Divergence in the approach to tumor necrosis factor α-inhibitor recipients with coccidioidomycosis

Ashley L. Garrett, Stephen S. Cha, Elizabeth Wack, Janis E. Blair

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Tumor necrosis factor α-inhibitors (TNFIs) have been associated with increased risk of certain fungal infections, including coccidioidomycosis. The optimal treatment approach to coccidioidomycosis in TNFI recipients is unknown. Methods: We constructed an anonymous, voluntary survey for practicing pulmonary and infectious disease physicians in the state of Arizona regarding approach to TNFI patients with coccidioidomycosis. Results: There is no current consensus on managing these patients. Conclusions: Further research is necessary to determine the optimal approach to TNFI recipients with coccidioidomycosis.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalInfection
DOIs
StateAccepted/In press - Jun 2 2017

Fingerprint

Coccidioidomycosis
Tumor Necrosis Factor-alpha
Mycoses
Lung Diseases
Communicable Diseases
Physicians
Research

Keywords

  • Biologic response modifiers
  • Coccidioides
  • Coccidioidomycosis
  • Infliximab
  • Tumor necrosis factor α-inhibitors
  • Valley fever

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Divergence in the approach to tumor necrosis factor α-inhibitor recipients with coccidioidomycosis. / Garrett, Ashley L.; Cha, Stephen S.; Wack, Elizabeth; Blair, Janis E.

In: Infection, 02.06.2017, p. 1-5.

Research output: Contribution to journalArticle

Garrett, Ashley L. ; Cha, Stephen S. ; Wack, Elizabeth ; Blair, Janis E. / Divergence in the approach to tumor necrosis factor α-inhibitor recipients with coccidioidomycosis. In: Infection. 2017 ; pp. 1-5.
@article{80a3ab1fd55c493a9b4f91e906da594f,
title = "Divergence in the approach to tumor necrosis factor α-inhibitor recipients with coccidioidomycosis",
abstract = "Background: Tumor necrosis factor α-inhibitors (TNFIs) have been associated with increased risk of certain fungal infections, including coccidioidomycosis. The optimal treatment approach to coccidioidomycosis in TNFI recipients is unknown. Methods: We constructed an anonymous, voluntary survey for practicing pulmonary and infectious disease physicians in the state of Arizona regarding approach to TNFI patients with coccidioidomycosis. Results: There is no current consensus on managing these patients. Conclusions: Further research is necessary to determine the optimal approach to TNFI recipients with coccidioidomycosis.",
keywords = "Biologic response modifiers, Coccidioides, Coccidioidomycosis, Infliximab, Tumor necrosis factor α-inhibitors, Valley fever",
author = "Garrett, {Ashley L.} and Cha, {Stephen S.} and Elizabeth Wack and Blair, {Janis E.}",
year = "2017",
month = "6",
day = "2",
doi = "10.1007/s15010-017-1029-9",
language = "English (US)",
pages = "1--5",
journal = "Infection",
issn = "0300-8126",
publisher = "Urban und Vogel",

}

TY - JOUR

T1 - Divergence in the approach to tumor necrosis factor α-inhibitor recipients with coccidioidomycosis

AU - Garrett, Ashley L.

AU - Cha, Stephen S.

AU - Wack, Elizabeth

AU - Blair, Janis E.

PY - 2017/6/2

Y1 - 2017/6/2

N2 - Background: Tumor necrosis factor α-inhibitors (TNFIs) have been associated with increased risk of certain fungal infections, including coccidioidomycosis. The optimal treatment approach to coccidioidomycosis in TNFI recipients is unknown. Methods: We constructed an anonymous, voluntary survey for practicing pulmonary and infectious disease physicians in the state of Arizona regarding approach to TNFI patients with coccidioidomycosis. Results: There is no current consensus on managing these patients. Conclusions: Further research is necessary to determine the optimal approach to TNFI recipients with coccidioidomycosis.

AB - Background: Tumor necrosis factor α-inhibitors (TNFIs) have been associated with increased risk of certain fungal infections, including coccidioidomycosis. The optimal treatment approach to coccidioidomycosis in TNFI recipients is unknown. Methods: We constructed an anonymous, voluntary survey for practicing pulmonary and infectious disease physicians in the state of Arizona regarding approach to TNFI patients with coccidioidomycosis. Results: There is no current consensus on managing these patients. Conclusions: Further research is necessary to determine the optimal approach to TNFI recipients with coccidioidomycosis.

KW - Biologic response modifiers

KW - Coccidioides

KW - Coccidioidomycosis

KW - Infliximab

KW - Tumor necrosis factor α-inhibitors

KW - Valley fever

UR - http://www.scopus.com/inward/record.url?scp=85020073895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020073895&partnerID=8YFLogxK

U2 - 10.1007/s15010-017-1029-9

DO - 10.1007/s15010-017-1029-9

M3 - Article

C2 - 28577242

AN - SCOPUS:85020073895

SP - 1

EP - 5

JO - Infection

JF - Infection

SN - 0300-8126

ER -